Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 4
4 · Upstream Bio, Inc. · Filed Oct 15, 2024
Insider Transaction Report
Form 4
Transactions
- Conversion
Series B redeemable convertible preferred stock
2024-10-15−852,940→ 0 total→ Common Stock (894,733 underlying) - Conversion
Common Stock
2024-10-15+894,733→ 894,733 total
Footnotes (1)
- [F1]Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date.